Investigational New Drug CDMO Market Size & Growth Forecast 2027–2036, By Segments (Service, End Use), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Investigational New Drug CDMO Market size stood at USD 5.5 billion in 2026 and is predicted to grow at a 8.27% CAGR from 2027 to 2036, crossing USD 12.17 billion by 2036. The industry revenue for 2027 is estimated at USD 5.88 billion.
Get more details on this report
Request Free Sample ReportInvestigational New Drug CDMO Market Intelligence Snapshot
Regional Market Dynamics
- North America accounted for a 43.67% market share in 2026, supported by its strong biotech ecosystem, mature outsourcing practices, and sustained demand for specialized early-stage drug development services.
- Asia Pacific is projected to expand at a 7.91% CAGR, driven by increasing outsourcing, expanding contract development infrastructure, and greater participation in early-phase pharmaceutical development programs.
Segment Momentum
- Contract Development held an 81.32% share in 2026 because sponsors rely on outsourced formulation, process development, analytical work, and regulatory documentation during the early stages of investigational drug programs.
- Biotech Companies are expanding fastest because they increasingly depend on CDMOs for technical, regulatory, and manufacturing support without investing in extensive in-house development infrastructure.
Market Expansion Drivers
- Rising pharmaceutical outsourcing demand driving rapid IND-stage development partnerships.
- Increasing complexity of biologics and oncology pipelines accelerating specialized CDMO service adoption.
- Integration of AI and digital lab technologies improving early-stage drug development efficiency.
Leading Market Participants
- Prominent players in the investigational new drug CDMO market include Lonza Group AG (Switzerland), Catalent, Inc. (United States), Thermo Fisher Scientific Inc. (United States), Charles River Laboratories International, Inc. (United States), Recipharm AB (Sweden), Siegfried Holding AG (Switzerland), Cambrex Corporation (United States), Piramal Pharma Solutions (India), Syngene International Limited (India).
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 5.5 billion
- 2027 Estimated Market Size: USD 5.88 billion.
- Projected Market Size: USD 12.17 billion by 2036
- Growth Forecast: 8.27% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Contract Development (Service) | Pharmaceutical Companies (End Use)
- Emerging Opportunity Segment: Contract Manufacturing (Service) | Biotech Companies (End Use)
Market Growth Drivers and Industry Trends
Rising pharmaceutical outsourcing demand driving rapid IND-stage development partnerships
Pharmaceutical and biotechnology organizations are increasingly outsourcing early-stage development activities to access specialized expertise and infrastructure without establishing all required capabilities internally. This shift will drive the investigational new drug CDMO market growth as development partnerships can support formulation, analytical testing, process development, manufacturing, and other activities required to advance drug candidates toward investigational new drug submissions. External development and manufacturing partners can also provide greater flexibility for organizations managing multiple pipeline programs with varying technical requirements. The need to shorten development timelines while maintaining quality and regulatory readiness is encouraging sponsors to engage specialized service providers during critical preclinical and early clinical stages.
Increasing complexity of biologics and oncology pipelines accelerating specialized CDMO service adoption
The growing complexity of biologics and oncology drug pipelines is increasing demand for development and manufacturing services with specialized scientific, technical, and analytical capabilities. Increasing pipeline sophistication will propel the investigational new drug CDMO market growth as sponsors require support in addressing challenges associated with complex molecular structures, advanced formulations, process scalability, and stringent development requirements. Specialized CDMOs can provide expertise across multiple stages of development, helping sponsors manage technical risks while preparing candidates for clinical evaluation. The increasing use of targeted and biologically complex therapies is also expanding the need for customized development strategies and advanced manufacturing capabilities.
Integration of AI and digital lab technologies improving early-stage drug development efficiency
Artificial intelligence and digital laboratory technologies are increasingly being incorporated into pharmaceutical research and development workflows to improve data utilization, experimental design, and process efficiency. The investigational new drug CDMO market demand is supported by these technologies as service providers can use advanced analytics and digital systems to streamline early-stage development activities and improve coordination across laboratory operations. AI-enabled tools can assist in identifying patterns within experimental data, optimizing selected processes, and supporting more informed development decisions. Digital laboratory infrastructure also improves data traceability and workflow integration across analytical, formulation, and process development activities.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Rising pharmaceutical outsourcing demand driving rapid IND-stage development partnerships | 2.20% | High | North America, Asia Pacific | High | Near Term |
| Increasing complexity of biologics and oncology pipelines accelerating specialized CDMO service adoption | 2.00% | High | North America, Europe | High | Mid Term |
| Integration of AI and digital lab technologies improving early-stage drug development efficiency | 1.80% | High | Global | Medium | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America accounted for the largest share of the investigational new drug CDMO market at 43.67% in 2026, reflecting the region's advanced pharmaceutical research ecosystem and strong concentration of early-stage drug development activities. Robust demand for outsourced development services is supported by the growing complexity of investigational therapies, the need for specialized formulation and analytical capabilities, and pharmaceutical developers' efforts to improve development efficiency. The region's established clinical research infrastructure, sophisticated regulatory environment, and availability of specialized scientific talent further support CDMO utilization from preclinical development through clinical-stage manufacturing. Increasing interest in complex molecules and innovative therapeutic approaches is also encouraging sponsors to engage external partners with flexible development and manufacturing capabilities.
Asia Pacific (Fastest-Growing Region)
Asia Pacific represents the fastest-growing regional market, benefiting from expanding pharmaceutical research capabilities, improving clinical development infrastructure, and increasing adoption of outsourced drug development services. Pharmaceutical and biotechnology companies are increasingly using regional CDMOs to access specialized expertise, manufacturing capacity, and cost-efficient development resources while supporting the advancement of investigational therapies. Improvements in regulatory frameworks, laboratory capabilities, and technical talent are strengthening the region's attractiveness for early-stage development programs. Rising investment in biotechnology and pharmaceutical innovation, combined with expanding participation in global drug development programs, is expected to accelerate demand for investigational new drug CDMO services across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
Germany 🇩🇪
Process Excellence BaseGermany emphasizes high-quality process development and GMP manufacturing for investigational new drug projects. CDMOs in Germany continue investing in advanced analytical capabilities to support complex pharmaceutical pipelines and multinational clinical studies.
France 🇫🇷
Translational Manufacturing NetworkFrance supports investigational new drug manufacturing through collaborations among research institutes, biotechnology firms, and specialized CDMOs. The country continues expanding capabilities for early-stage biologics production and regulatory-ready manufacturing services.
Italy 🇮🇹
Specialized Development ServicesItaly focuses on niche investigational manufacturing services for pharmaceutical innovators requiring flexible production and formulation expertise. Italian CDMOs continue expanding customized development capabilities to support diverse clinical-stage drug candidates.
Japan 🇯🇵
Precision Development FocusJapan prioritizes reliable investigational manufacturing supported by stringent quality standards and close collaboration between innovators and CDMOs. Japanese pharmaceutical developers increasingly seek specialized expertise for biologics and advanced therapeutic candidates.
South Korea 🇰🇷
Biotech Scale-Up PlatformSouth Korea is strengthening investigational new drug CDMO capabilities through investments in biopharmaceutical infrastructure and technology platforms. Domestic and international developers increasingly utilize South Korea for rapid process development and clinical manufacturing support.
United States 🇺🇸
Clinical Development HubThe U.S. investigational new drug CDMO market benefits from sustained demand for early-phase biologics, cell therapies, and small-molecule programs. Sponsors increasingly prioritize flexible manufacturing capacity and integrated regulatory support to accelerate IND submissions.
Segment Leadership and Growth Trends
Investigational New Drug CDMO Market Share (%), by Service, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportService Segment Analysis: Contract Development (Largest Segment) vs Contract Manufacturing (Fastest-Growing Segment)
Contract development dominated the investigational new drug CDMO market with an 81.32% share in 2026, reflecting strong demand for specialized support during the early stages of drug development. Development services help sponsors address formulation, analytical, process development, and other technical requirements while accessing external expertise and infrastructure. The increasing complexity of investigational therapies and the need to accelerate development workflows are encouraging pharmaceutical developers to rely on specialized CDMO capabilities. This outsourcing model enables sponsors to manage development requirements more efficiently while progressing candidates toward clinical evaluation.
Contract manufacturing is gaining momentum as drug developers increasingly seek flexible external production capabilities for investigational materials and clinical-stage programs. Outsourcing manufacturing can reduce the need for sponsors to build dedicated production infrastructure while providing access to specialized facilities and manufacturing expertise. Rising development activity among emerging therapeutic developers, increasing complexity of production requirements, and the need for reliable clinical supply are supporting stronger demand for contract manufacturing services.
End Use Segment Analysis: Pharmaceutical Companies (Largest Segment) vs Biotech Companies (Fastest-Growing Segment)
Pharmaceutical companies represented the largest end-use segment of the investigational new drug CDMO market in 2026, supported by their extensive drug development pipelines and recurring need for specialized external development and manufacturing capabilities. Outsourcing enables pharmaceutical organizations to supplement internal resources, manage complex development programs, and access specialized technical infrastructure without expanding every capability internally. The continued pursuit of new therapies and increasing emphasis on development efficiency sustain strong utilization of CDMO services among established pharmaceutical developers.
Biotech companies are emerging as the fastest-growing end-use group as smaller and innovation-focused developers increasingly depend on external partners to advance drug candidates through development stages. Limited internal infrastructure and specialized manufacturing capabilities make CDMO outsourcing particularly valuable for biotechnology developers seeking to conserve resources while accessing technical expertise. Increasing innovation in complex and novel therapeutic modalities is further strengthening the need for flexible development and manufacturing support.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Service | Contract Development, Contract Manufacturing | Contract Development | Contract Manufacturing |
| End Use | Pharmaceutical Companies, Biotech Companies, Others | Pharmaceutical Companies | Biotech Companies |
Competitive Landscape and Market Positioning
Leading companies in the investigational new drug CDMO market:
1. Lonza Group AG (Switzerland)
2. Catalent Inc. (United States)
3. Thermo Fisher Scientific Inc. (United States)
4. Charles River Laboratories International Inc. (United States)
5. Recipharm AB (Sweden)
6. Siegfried Holding AG (Switzerland)
7. Cambrex Corporation (United States)
8. Piramal Pharma Solutions (India)
9. Syngene International Limited (India)
The investigational new drug CDMO market is advancing through integrated drug development services that streamline clinical trial manufacturing and regulatory pathways. Continuous innovation is improving process scalability and development efficiency. Expanding collaboration ecosystems are strengthening end-to-end pharmaceutical development capabilities.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Lonza Group AG (Switzerland) | |||||||
| Catalent Inc. (United States) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| Charles River Laboratories International Inc. (United States) | |||||||
| Recipharm AB (Sweden) | |||||||
| Siegfried Holding AG (Switzerland) | |||||||
| Cambrex Corporation (United States) | |||||||
| Piramal Pharma Solutions (India) | |||||||
| Syngene International Limited (India). |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Porton Advanced | Apr-25 | Porton Advanced entered a CDMO collaboration with Tasly Pharmaceutical on the development of the dual-targeting CAR-T therapy “P134 Cell Injection,” which received IND clearance from China’s NMPA. The therapy targets recurrent glioblastoma, reflecting expansion of advanced cell therapy manufacturing capabilities within investigational biologics development. |
| Lonza | Mar-24 | Lonza agreed to acquire a U.S. biologics manufacturing facility from Roche for USD 1.2 billion, with plans to invest an additional USD 500 million for upgrades. The transaction is aimed at expanding biologics production capacity, strengthening Lonza’s U.S. manufacturing footprint, and supporting growing demand for next-generation biologic and investigational drug development services. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Investigational New Drug CDMO Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Therapeutic Area | Oncology, Neurology, Infectious Diseases, Immunology & Autoimmune Disorders, Cardiovascular Diseases, Other Therapeutic Areas |
| Molecule Type | Small Molecules, Biologics, Cell & Gene Therapies, Other Molecule Types |
| Development Phase | Preclinical Development, Phase I, Phase II, Phase III |
Investigational New Drug CDMO Market — Custom
| Custom Chapter | Custom Details |
|---|---|
| Early-stage Drug Development Outsourcing Analysis |
|
| Biotech Client Acquisition Opportunity Mapping |
|
| CDMO Capacity Expansion Strategy |
|
Need a different cut of the data?
Request Custom ResearchWhat is the current revenue of the investigational new drug CDMO market?
How much is the investigational new drug CDMO industry expected to grow by 2036?
How is pharmaceutical outsourcing pressure shaping demand for IND-stage CDMO services?
How are biologics complexity and digital technologies transforming CDMO service models in IND development?
Why is Contract Development the largest service segment in the investigational new drug CDMO market?
Why are Biotech Companies the fastest-growing end users in the investigational new drug CDMO market?
Why does North America lead the investigational new drug CDMO market?
What is accelerating investigational new drug CDMO market growth in Asia Pacific?
Which companies are driving growth in the investigational new drug CDMO landscape?
Our Clients
"The reports offered a comprehensive view of the Food and Beverage landscape, covering market trends, consumer behavior, and competitive dynamics."
"Our experience in acquiring market research reports has been outstanding — the depth of analysis and actionable insights have proven invaluable."
"Fundamental Business Insights demonstrated a keen understanding of our business needs, delivering reports tailored to our specific objectives."
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Why It Matters | Reference |
|---|---|---|
| World Health Organization (WHO) | Global health statistics, disease burden, healthcare policies | www.who.int |
| U.S. Food & Drug Administration (FDA) | Medical devices, pharmaceuticals, diagnostics, approvals | www.fda.gov |
| European Medicines Agency (EMA) | Pharmaceutical approvals and regulatory guidance in Europe | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | Disease surveillance, public health, epidemiology | www.cdc.gov |
| National Institutes of Health (NIH) | Biomedical research, clinical studies, funding | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | Biomedical databases, PubMed, genomics | www.ncbi.nlm.nih.gov |
| PubMed | Peer-reviewed biomedical literature | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | Global clinical trial registry | clinicaltrials.gov |
| International Organization for Standardization (ISO) | Medical device quality and healthcare standards | www.iso.org |
| ASTM International | Medical device testing and material standards | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | Medical devices and diagnostics industry | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | Medical device innovation and regulatory science | mdic.org |
| Biotechnology Innovation Organization (BIO) | Biotechnology industry developments | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | Global pharmaceutical industry | www.ifpma.org |
| U.S. Pharmacopeia (USP) | Drug quality standards and reference materials | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | European pharmaceutical quality standards | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | Veterinary healthcare and animal diseases | www.woah.org |
| American Hospital Association (AHA) | Hospital operations and healthcare delivery | www.aha.org |
| OECD Health | International healthcare expenditure and system statistics | www.oecd.org/health |
| World Bank Data | Healthcare expenditure and demographic indicators | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization